Jim Simons
DNLI icon

Jim Simons’s Denali Therapeutics DNLI Stock Holding History

Jim Simons’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,700
Closed -$177K – 3338
2025
Q4 		$177K Sell
10,700
-49,100
-82% -$829K ﹤0.01% 2909
2025
Q3 		$868K Sell
59,800
-135,900
-69% -$1.95M ﹤0.01% 2561
2025
Q2 		$2.74M Buy
195,700
+22,600
+13% +$318K ﹤0.01% 1915
2025
Q1 		$2.35M Buy
+173,100
New +$3.32M ﹤0.01% 1900
2024
Q1 		– Sell
-161,946
Closed -$3.48M – 3778
2023
Q4 		$3.48M Sell
161,946
-305,905
-65% -$6.06M 0.01% 1581
2023
Q3 		$9.65M Buy
467,851
+51
+0% +$1.29K 0.02% 944
2023
Q2 		$13.8M Buy
467,800
+59,700
+15% +$1.68M 0.02% 860
2023
Q1 		$9.4M Buy
408,100
+158,500
+64% +$4.36M 0.01% 1114
2022
Q4 		$6.94M Sell
249,600
-142,600
-36% -$4.24M 0.01% 1301
2022
Q3 		$12M Buy
392,200
+138,700
+55% +$4.51M 0.02% 932
2022
Q2 		$7.46M Buy
253,500
+130,900
+107% +$3.43M 0.01% 1281
2022
Q1 		$3.94M Buy
122,600
+68,300
+126% +$2.35M ﹤0.01% 1757
2021
Q4 		$2.42M Sell
54,300
-41,300
-43% -$1.96M ﹤0.01% 1988
2021
Q3 		$4.82M Buy
95,600
+84,100
+731% +$4.74M 0.01% 1485
2021
Q2 		$902K Sell
11,500
-254,400
-96% -$15.7M ﹤0.01% 2718
2021
Q1 		$15.2M Buy
+265,900
New +$17.8M 0.02% 937
2020
Q4 		– Sell
-51,500
Closed -$1.84M – 3443
2020
Q3 		$1.84M Buy
+51,500
New +$1.55M ﹤0.01% 2187
2019
Q3 		– Sell
-63,000
Closed -$1.31M – 3468
2019
Q2 		$1.31M Buy
+63,000
New +$1.41M ﹤0.01% 2564

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's DNLI Position: Q1 2026 in Review

Jim Simons sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 10,700 shares — an estimated $177K sold.

Jim Simons first reported a position in DNLI in Q2 2019 and held it in 18 quarters. The position peaked at $15.2M in Q1 2021. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Jim Simons reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jim Simons sold 10,700 Denali Therapeutics shares in Q1 2026, an estimated $177K.
  • Jim Simons first reported a position in Denali Therapeutics in Q2 2019 and held it in 18 quarters.
  • Jim Simons's Denali Therapeutics position peaked at $15.2M in Q1 2021.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.